ME02024B - Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze - Google Patents

Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze

Info

Publication number: ME02024B
Authority: ME; Montenegro
Prior art keywords: hcv; protease inhibitors; quinoxaline compounds; macrocyclic; macrocyclic quinoxaline
Prior art date: 2008-07-22

Application number

MEP-2012-463A

Other languages

English (en)

Inventor

Steven Harper

Vincenzo Summa

Nigel J Liverton

Johh A Mccauley

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-22

Filing date

2009-07-17

Publication date

2015-05-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-17 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2015-05-20 Publication of ME02024B publication Critical patent/ME02024B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MEP-2012-463A 2008-07-22 2009-07-17 Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze ME02024B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13555908P	2008-07-22	2008-07-22
EP09790553A EP2310095B1 (en)	2008-07-22	2009-07-17	Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
PCT/US2009/050915 WO2010011566A1 (en)	2008-07-22	2009-07-17	Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors

Publications (1)

Publication Number	Publication Date
ME02024B true ME02024B (me)	2015-05-20

Family

ID=41130248

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MEP-2012-463A ME02024B (me)	2008-07-22	2009-07-17	Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
MEP-2014-375A ME02132B (me)	2008-07-22	2009-07-17	Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MEP-2014-375A ME02132B (me)	2008-07-22	2009-07-17	Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima

Country Status (44)

Country	Link
US (2)	US7973040B2 (me)
EP (3)	EP2310095B1 (me)
JP (1)	JP4920797B2 (me)
KR (1)	KR101313675B1 (me)
CN (1)	CN102159285B (me)
AR (1)	AR072588A1 (me)
AU (1)	AU2009274190B2 (me)
BR (1)	BRPI0916235B8 (me)
CA (1)	CA2731177C (me)
CL (1)	CL2011000145A1 (me)
CO (1)	CO6351757A2 (me)
CR (1)	CR20110089A (me)
CY (3)	CY1113752T1 (me)
DK (2)	DK2310095T3 (me)
DO (1)	DOP2011000023A (me)
EA (1)	EA019327B1 (me)
EC (1)	ECSP11010777A (me)
ES (2)	ES2491090T3 (me)
FR (1)	FR16C1027I2 (me)
HK (2)	HK1173402A1 (me)
HN (1)	HN2011000209A (me)
HR (2)	HRP20120866T1 (me)
HU (1)	HUS1700001I1 (me)
IL (1)	IL210580A (me)
LT (1)	LTC2310095I2 (me)
LU (1)	LUC00002I2 (me)
MA (1)	MA32502B1 (me)
ME (2)	ME02024B (me)
MX (1)	MX2011000826A (me)
MY (1)	MY152070A (me)
NI (1)	NI201100023A (me)
NL (1)	NL300857I2 (me)
NO (1)	NO2017004I2 (me)
NZ (1)	NZ590638A (me)
PE (1)	PE20110212A1 (me)
PL (2)	PL2310095T3 (me)
PT (2)	PT2310095E (me)
RS (2)	RS52534B (me)
SI (2)	SI2540350T1 (me)
SV (1)	SV2011003813A (me)
TN (1)	TN2011000014A1 (me)
TW (1)	TWI441638B (me)
UA (1)	UA100436C2 (me)
WO (1)	WO2010011566A1 (me)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en) *	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
BRPI0718161A2 (pt) *	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
US8461107B2 (en) *	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
EA019327B1 (ru)	2008-07-22	2014-02-28	Мерк Шарп Энд Домэ Корп.	Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
EP2410844B1 (en)	2009-03-27	2016-03-23	Merck Sharp & Dohme Corp.	Inhibitors of hepatitis c virus replication
US20190127365A1 (en)	2017-11-01	2019-05-02	Merck Sharp & Dohme Corp.	Inhibitors of hepatitis c virus replication
JP5639155B2 (ja) *	2009-05-13	2014-12-10	エナンタファーマシューティカルズインコーポレイテッド	Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
RS53856B1 (en) *	2009-06-11	2015-08-31	Abbvie Bahamas Ltd.	HETEROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
WO2011014487A1 (en)	2009-07-30	2011-02-03	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
KR101894704B1 (ko) *	2010-09-21	2018-09-05	이난타 파마슈티칼스, 인코포레이티드	매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
JP2013544232A (ja) *	2010-09-29	2013-12-12	メルク・シャープ・エンド・ドーム・コーポレイション	多環式複素環誘導体ならびにウィルス疾患の治療のための方法およびそれの使用
WO2012050848A1 (en)	2010-09-29	2012-04-19	Schering Corporation	Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US9120818B2 (en)	2010-12-14	2015-09-01	Merck Sharp & Dohme Corp.	Process and intermediates for preparing macrolactams
WO2012122716A1 (en)	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US9249204B2 (en) *	2011-06-01	2016-02-02	Jyant Technologies, Inc.	Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
EP2744507A4 (en) *	2011-08-19	2015-01-28	Merck Sharp & Dohme	CRYSTAL FORMS OF AN HCV PROTEASE HEMMER
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
PH12014500832A1 (en)	2011-10-21	2022-12-02	Abbvie Inc	Methods for treating hcv
JP5677646B2 (ja)	2011-10-21	2015-02-25	アッヴィ・インコーポレイテッド	Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
JP2015513520A (ja) *	2011-10-31	2015-05-14	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ウイルス疾患の治療に有用な組成物
WO2013074386A2 (en)	2011-11-15	2013-05-23	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
EP2909205B1 (en)	2012-10-19	2016-11-23	Bristol-Myers Squibb Company	9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
US9598433B2 (en)	2012-11-02	2017-03-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914598B1 (en)	2012-11-02	2017-10-18	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914614B1 (en)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014110687A1 (en)	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EP2964664B1 (en)	2013-03-07	2017-01-11	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
CA2902569A1 (en) *	2013-03-15	2014-09-18	Gilead Sciences, Inc.	Inhibitors of hepatitis c virus
SG11201602693QA (en) *	2013-10-18	2016-05-30	Merck Sharp & Dohme	Methods and intermediates for preparing macrolactams
WO2015095430A1 (en) *	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Methods and intermediates for the preparation of macrolactams
AU2014370125B2 (en) *	2013-12-23	2017-11-16	Gilead Sciences, Inc.	Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
WO2015100144A1 (en) *	2013-12-23	2015-07-02	Gilead Sciences, Inc.	Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
US20160339074A1 (en) *	2014-02-05	2016-11-24	Merck Sharp & Dohme Corp.	Pharmaceutical composition of selective hcv ns3/4a inhibitors
CA2937942A1 (en) *	2014-02-05	2015-08-13	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
AU2015269306B2 (en)	2014-06-06	2020-06-25	Abbvie Inc.	Crystal forms
WO2017023716A1 (en) *	2015-08-04	2017-02-09	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20180228826A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
CN105753806B (zh) *	2016-02-02	2018-06-05	厦门市蔚嘉化学科技有限公司	一种利托那韦中间体的非均相合成方法及其应用
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP4483875A2 (en)	2016-05-10	2025-01-01	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
CN112661775A (zh) *	2016-05-16	2021-04-16	深圳市塔吉瑞生物医药有限公司	一种取代的大环喹喔啉化合物及其药物组合物及应用
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US20220227806A1 (en) *	2019-06-07	2022-07-21	University Of Massachusetts	Hepatitis c virus ns3/4a protease inhibitors
CN111057045A (zh) *	2019-12-18	2020-04-24	安徽红杉生物医药科技有限公司	Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3480613A (en)	1967-07-03	1969-11-25	Merck & Co Inc	2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US6128582A (en)	1996-04-30	2000-10-03	Vertex Pharmaceuticals Incorporated	Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
IL134232A0 (en)	1997-08-11	2001-04-30	Boehringer Ingelheim Ca Ltd	Hepatitis c inhibitor peptides
ES2234144T3 (es)	1997-08-11	2005-06-16	Boehringer Ingelheim (Canada) Ltd.	Analogos de peptidos inhibidores de la hepatitis c.
IT1299134B1 (it)	1998-02-02	2000-02-29	Angeletti P Ist Richerche Bio	Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
DK1058686T3 (da)	1998-02-25	2007-03-05	Univ Emory	2'-fluornukleosider
GB9806815D0 (en)	1998-03-30	1998-05-27	Hoffmann La Roche	Amino acid derivatives
EP1066247B1 (en)	1998-03-31	2006-11-22	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en)	1998-06-10	1998-08-05	Angeletti P Ist Richerche Bio	Peptide inhibitors of hepatitis c virus ns3 protease
WO2000009546A1 (fr)	1998-08-10	2000-02-24	Hokkaido Electric Power Company, Incorporated	Preparation de glycopeptides ordinaires
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
CA2348234A1 (en)	1998-10-29	2000-05-11	Chunjian Liu	Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU780973B2 (en)	1999-06-25	2005-04-28	Vertex Pharmaceuticals Incorporated	Prodrugs of carbamate inhibitors of IMPDH
CN1623984A (zh)	1999-12-27	2005-06-08	日本烟草产业株式会社	稠环化合物及其药物用途
US6495677B1 (en)	2000-02-15	2002-12-17	Kanda S. Ramasamy	Nucleoside compounds
US6455508B1 (en)	2000-02-15	2002-09-24	Kanda S. Ramasamy	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
CN1427722A (zh)	2000-02-18	2003-07-02	希拉生物化学股份有限公司	用核苷类似物治疗或预防黄病毒感染的方法
MXPA02009920A (es)	2000-04-05	2003-03-27	Schering Corp	Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c9 que comprenden partes p2 n-ciclicas.
AU2001253206A1 (en)	2000-04-05	2001-10-23	Tularik, Inc.	Ns5b hcv polymerase inhibitors
US7094770B2 (en)	2000-04-13	2006-08-22	Pharmasset, Ltd.	3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko)	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
GB0017676D0 (en)	2000-07-19	2000-09-06	Angeletti P Ist Richerche Bio	Inhibitors of viral polymerase
WO2002014376A2 (en)	2000-08-10	2002-02-21	Trustees Of Boston College	Recyclable metathesis catalysts
US6955174B2 (en)	2000-08-18	2005-10-18	Uryovascular Systems, Inc.	Cryotherapy method for detecting and treating vulnerable plaque
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
US6809101B2 (en)	2000-09-01	2004-10-26	Shionogi & Co., Ltd.	Compounds having anti-hepatitis C virus effect
US20030087873A1 (en)	2000-10-18	2003-05-08	Lieven Stuyver	Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
HUP0303436A2 (hu)	2000-12-12	2004-01-28	Schering Corp.	Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2002230763A1 (en)	2000-12-13	2008-01-03	Bristol-Myers Squibb Pharma Company	Inhibitors of hepatitis c virus ns3 protease
KR20030081343A (ko)	2000-12-15	2003-10-17	파마셋, 리미티드	플라비비리다에 감염 치료용 항바이러스제
US20040063651A1 (en)	2000-12-26	2004-04-01	Masahiko Morioka	Remedies for hepatitis c
GEP20053601B (en)	2001-01-22	2005-08-10	Merck & Co Inc	Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral Polymerase
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
ES2607802T3 (es)	2001-08-14	2017-04-04	Tel Aviv University Future Technology Development L.P.	Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia
AU2002330154A1 (en)	2001-09-28	2003-04-07	Centre National De La Recherche Scientifique	Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP2005536440A (ja)	2001-09-28	2005-12-02	イデニクス（ケイマン）リミテツド	４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
JP2005515254A (ja)	2002-01-17	2005-05-26	スミスクラインビーチャムコーポレーション	カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
GB0201179D0 (en)	2002-01-18	2002-03-06	Angeletti P Ist Richerche Bio	Therapeutic agents
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
WO2003068244A1 (en)	2002-02-13	2003-08-21	Merck & Co., Inc.	Methods of inhibiting orthopoxvirus replication with nucleoside compounds
WO2003082887A1 (en)	2002-03-28	2003-10-09	Council Of Scientific And Industrial Research	8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, process of isolation from pterocarpus marsupium and pharmaceutical composition for the treatment of diabetes
BR0309581A (pt)	2002-05-06	2005-03-29	Genelabs Tech Inc	Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
EP1551421A2 (en)	2002-06-21	2005-07-13	Merck & Co. Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20060234962A1 (en)	2002-06-27	2006-10-19	Olsen David B	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7662798B2 (en)	2002-06-28	2010-02-16	Idenix Pharmaceuticals, Inc.	2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MY140819A (en)	2002-06-28	2010-01-29	Idenix Caymans Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
EP1525209B1 (en)	2002-06-28	2017-11-15	Idenix Pharmaceuticals LLC	1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections
US20060264389A1 (en)	2002-07-16	2006-11-23	Balkrishen Bhat	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003254657A1 (en)	2002-07-25	2004-02-16	Micrologix Biotech Inc.	Anti-viral 7-deaza d-nucleosides and uses thereof
BR0313164A (pt)	2002-08-01	2007-07-17	Pharmasset Inc	compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
WO2004028481A2 (en)	2002-09-30	2004-04-08	Genelabs Technologies, Inc.	Nucleoside derivatives for treating hepatitis c virus infection
EP1581207A4 (en)	2002-11-01	2007-07-25	Viropharma Inc	BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING AND PROPHYLAXIS OF VIRAL INFECTIONS WITH HEPATITIS C AND RELATED ILLNESSES
US20040254159A1 (en)	2003-02-27	2004-12-16	Hasvold Lisa A.	Heterocyclic kinase inhibitors
CA2516016C (en)	2003-03-05	2012-05-29	Boehringer Ingelheim International Gmbh	Hepatitis c inhibiting compounds
EA010013B1 (ru)	2003-04-02	2008-06-30	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтические композиции ингибиторов вирусной протеазы гепатита с
GB0307891D0 (en)	2003-04-04	2003-05-14	Angeletti P Ist Richerche Bio	Chemical compounds,compositions and uses
JP4733023B2 (ja)	2003-04-16	2011-07-27	ブリストル−マイヤーズスクイブカンパニー	Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7176208B2 (en)	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MY143076A (en)	2003-05-21	2011-02-28	Boehringer Ingelheim Int	Hepatitis c inhibitors compounds
PT2604620T (pt)	2003-05-30	2016-08-18	Gilead Pharmasset Llc	Analogos de nucleósido fluorados modificados
GB0313250D0 (en)	2003-06-09	2003-07-16	Angeletti P Ist Richerche Bio	Therapeutic agents
MXPA05013452A (es)	2003-06-19	2006-03-09	Hoffmann La Roche	Proceso para preparar derivados de 4'-azidonucleosido.
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
GB0321003D0 (en)	2003-09-09	2003-10-08	Angeletti P Ist Richerche Bio	Compounds, compositions and uses
GB0323845D0 (en)	2003-10-10	2003-11-12	Angeletti P Ist Richerche Bio	Chemical compounds,compositions and uses
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
ES2358333T3 (es)	2004-01-21	2011-05-09	Boehringer Ingelheim International Gmbh	Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
DK1719773T3 (da)	2004-02-24	2009-06-29	Japan Tobacco Inc	Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
GB0413087D0 (en)	2004-06-11	2004-07-14	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0416396D0 (en)	2004-07-22	2004-08-25	Angeletti P Ist Richerche Bio	Therapeutic agents
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
EP1794172B1 (en)	2004-08-23	2009-07-15	F.Hoffmann-La Roche Ag	Antiviral 4'-azido-nucleosides
GB0419850D0 (en)	2004-09-07	2004-10-13	Angeletti P Ist Richerche Bio	Therapeutic agents
AU2005298403A1 (en)	2004-10-26	2006-05-04	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Tetracyclic indole derivatives as antiviral agents
US7834145B2 (en)	2005-03-22	2010-11-16	Merck Sharp & Dohme Corp.	HCV protease substrates
JP4705164B2 (ja)	2005-05-02	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
GB0509326D0 (en)	2005-05-09	2005-06-15	Angeletti P Ist Richerche Bio	Therapeutic compounds
TWI387603B (zh)	2005-07-20	2013-03-01	Merck Sharp & Dohme	Ｈｃｖｎｓ３蛋白酶抑制劑
US7462035B2 (en)	2005-07-27	2008-12-09	Physical Optics Corporation	Electrical connector configured as a fastening element
EP1913016B1 (en)	2005-08-01	2013-01-16	Merck Sharp & Dohme Corp.	Macrocyclic peptides as hcv ns3 protease inhibitors
WO2007028789A1 (en)	2005-09-07	2007-03-15	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Quinazoline derivatives as antiviral agents
GB0518390D0 (en)	2005-09-09	2005-10-19	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0519797D0 (en)	2005-09-29	2005-11-09	Istituto Di Ricerche D Biolog	Therapeutic agents
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
WO2007145894A2 (en)	2006-06-08	2007-12-21	Merck & Co., Inc.	A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
AR061629A1 (es) *	2006-06-26	2008-09-10	Enanta Pharm Inc	Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
AU2007309544B2 (en) *	2006-10-24	2012-05-31	Msd Italia S.R.L.	HCV NS3 protease inhibitors
JP5345941B2 (ja)	2006-10-24	2013-11-20	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
AU2007309546A1 (en)	2006-10-24	2008-05-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	HCV NS3 protease inhibitors
JP5352464B2 (ja) *	2006-10-27	2013-11-27	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
BRPI0718161A2 (pt) *	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
WO2008057028A1 (en)	2006-11-09	2008-05-15	Twinblade Technologies Holding Sweden Ab	Hub device
EP2118301A4 (en)	2007-03-09	2011-04-20	Merck Sharp & Dohme	IN VIVO HCV RESISTANCE TO ANTI-VIRAL HEMMER
CN101784548B (zh)	2007-06-29	2013-07-17	吉里德科学公司	嘌呤衍生物及其作为toll样受体7的调节剂的用途
CN101754974B (zh)	2007-07-19	2016-02-03	Msd意大利有限公司	作为抗病毒剂的大环化合物
CN102026544A (zh)	2007-11-14	2011-04-20	益安药业	大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂
CL2008003384A1 (es)	2007-11-14	2009-12-11	Enanta Pharm Inc	Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8461107B2 (en) *	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
EA019327B1 (ru)	2008-07-22	2014-02-28	Мерк Шарп Энд Домэ Корп.	Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3

2009
- 2009-07-17 EA EA201170241A patent/EA019327B1/ru active Protection Beyond IP Right Term
- 2009-07-17 MY MYPI20110310 patent/MY152070A/en unknown
- 2009-07-17 JP JP2011520110A patent/JP4920797B2/ja active Active
- 2009-07-17 DK DK09790553.3T patent/DK2310095T3/da active
- 2009-07-17 SI SI200930956T patent/SI2540350T1/sl unknown
- 2009-07-17 AU AU2009274190A patent/AU2009274190B2/en active Active
- 2009-07-17 SI SI200930359T patent/SI2310095T1/sl unknown
- 2009-07-17 DK DK12181546.8T patent/DK2540350T3/da active
- 2009-07-17 US US12/504,955 patent/US7973040B2/en active Active
- 2009-07-17 PE PE2011000067A patent/PE20110212A1/es active IP Right Grant
- 2009-07-17 NZ NZ590638A patent/NZ590638A/en not_active IP Right Cessation
- 2009-07-17 EP EP09790553A patent/EP2310095B1/en active Active
- 2009-07-17 PT PT09790553T patent/PT2310095E/pt unknown
- 2009-07-17 BR BRPI0916235A patent/BRPI0916235B8/pt active IP Right Grant
- 2009-07-17 ME MEP-2012-463A patent/ME02024B/me unknown
- 2009-07-17 RS RS20120463A patent/RS52534B/en unknown
- 2009-07-17 MX MX2011000826A patent/MX2011000826A/es active IP Right Grant
- 2009-07-17 KR KR1020117003982A patent/KR101313675B1/ko active Protection Beyond IP Right Term
- 2009-07-17 WO PCT/US2009/050915 patent/WO2010011566A1/en active Application Filing
- 2009-07-17 RS RS20140375A patent/RS53420B/en unknown
- 2009-07-17 PT PT121815468T patent/PT2540350E/pt unknown
- 2009-07-17 EP EP12181546.8A patent/EP2540350B1/en active Active
- 2009-07-17 EP EP12181533.6A patent/EP2540349B1/en active Active
- 2009-07-17 PL PL09790553T patent/PL2310095T3/pl unknown
- 2009-07-17 PL PL12181546T patent/PL2540350T3/pl unknown
- 2009-07-17 ES ES12181546.8T patent/ES2491090T3/es active Active
- 2009-07-17 ME MEP-2014-375A patent/ME02132B/me unknown
- 2009-07-17 UA UAA201102068A patent/UA100436C2/uk unknown
- 2009-07-17 ES ES09790553T patent/ES2392611T3/es active Active
- 2009-07-17 CN CN200980137118.6A patent/CN102159285B/zh active Active
- 2009-07-17 CA CA2731177A patent/CA2731177C/en active Active
- 2009-07-21 AR ARP090102779A patent/AR072588A1/es active IP Right Grant
- 2009-07-21 TW TW098124597A patent/TWI441638B/zh active
2011
- 2011-01-11 IL IL210580A patent/IL210580A/en active Protection Beyond IP Right Term
- 2011-01-13 TN TN2011000014A patent/TN2011000014A1/fr unknown
- 2011-01-19 NI NI201100023A patent/NI201100023A/es unknown
- 2011-01-19 CO CO11005448A patent/CO6351757A2/es active IP Right Grant
- 2011-01-20 DO DO2011000023A patent/DOP2011000023A/es unknown
- 2011-01-20 HN HN2011000209A patent/HN2011000209A/es unknown
- 2011-01-20 SV SV2011003813A patent/SV2011003813A/es unknown
- 2011-01-21 CL CL2011000145A patent/CL2011000145A1/es unknown
- 2011-01-21 EC EC2011010777A patent/ECSP11010777A/es unknown
- 2011-01-25 MA MA33556A patent/MA32502B1/fr unknown
- 2011-02-15 CR CR20110089A patent/CR20110089A/es unknown
- 2011-05-20 US US13/112,281 patent/US8080654B2/en active Active
2012
- 2012-10-26 HR HRP20120866AT patent/HRP20120866T1/hr unknown
- 2012-11-28 CY CY20121101150T patent/CY1113752T1/el unknown
2013
- 2013-01-15 HK HK13100580.1A patent/HK1173402A1/xx unknown
- 2013-01-15 HK HK13100581.0A patent/HK1173403A1/xx unknown
2014
- 2014-07-18 HR HRP20140693AT patent/HRP20140693T1/hr unknown
- 2014-08-01 CY CY20141100582T patent/CY1115503T1/el unknown
2016
- 2016-12-26 FR FR16C1027C patent/FR16C1027I2/fr active Active
- 2016-12-29 LT LTPA2016049C patent/LTC2310095I2/lt unknown
- 2016-12-30 NL NL300857C patent/NL300857I2/nl unknown
2017
- 2017-01-03 LU LU00002C patent/LUC00002I2/fr unknown
- 2017-01-10 HU HUS1700001C patent/HUS1700001I1/hu unknown
- 2017-01-20 NO NO2017004C patent/NO2017004I2/no unknown
- 2017-01-20 CY CY2017005C patent/CY2017005I1/el unknown

Also Published As

Publication number	Publication date
EA019327B1 (ru)	2014-02-28
ECSP11010777A (es)	2011-02-28
EP2310095A1 (en)	2011-04-20
HRP20140693T1 (hr)	2014-11-21
WO2010011566A1 (en)	2010-01-28
CL2011000145A1 (es)	2011-05-06
EP2540350A1 (en)	2013-01-02
ES2392611T3 (es)	2012-12-12
MX2011000826A (es)	2011-02-23
PE20110212A1 (es)	2011-04-10
CY1115503T1 (el)	2017-01-04
TW201023860A (en)	2010-07-01
PL2310095T3 (pl)	2013-03-29
TN2011000014A1 (en)	2012-09-05
HK1173402A1 (en)	2013-05-16
JP4920797B2 (ja)	2012-04-18
EP2310095B1 (en)	2012-08-29
DOP2011000023A (es)	2011-03-31
CY2017005I2 (el)	2017-06-28
HN2011000209A (es)	2013-04-22
CY2017005I1 (el)	2017-06-28
LTC2310095I2 (lt)	2018-11-12
BRPI0916235A8 (pt)	2018-06-12
TWI441638B (zh)	2014-06-21
AU2009274190B2 (en)	2012-07-05
FR16C1027I1 (fr)	2017-02-03
NO2017004I1 (no)	2017-01-20
RS53420B (en)	2014-12-31
CN102159285B (zh)	2014-05-14
NI201100023A (es)	2011-09-20
CR20110089A (es)	2011-04-27
SI2540350T1 (sl)	2015-01-30
US20110224134A1 (en)	2011-09-15
HK1173403A1 (en)	2013-05-16
HUS1700001I1 (hu)	2017-02-28
ME02132B (me)	2014-08-22
DK2540350T3 (da)	2014-08-04
EP2540349B1 (en)	2014-02-12
PT2540350E (pt)	2014-08-27
EA201170241A1 (ru)	2011-10-31
EP2540350B1 (en)	2014-05-21
SV2011003813A (es)	2011-05-25
AR072588A1 (es)	2010-09-08
BRPI0916235B8 (pt)	2021-05-25
LUC00002I1 (me)	2017-01-19
FR16C1027I2 (fr)	2017-12-08
SI2310095T1 (sl)	2013-01-31
MA32502B1 (fr)	2011-07-03
MY152070A (en)	2014-08-15
LTPA2016049I1 (lt)	2017-01-25
CN102159285A (zh)	2011-08-17
CY1113752T1 (el)	2016-07-27
US20100029666A1 (en)	2010-02-04
BRPI0916235B1 (pt)	2020-09-29
EP2540349A1 (en)	2013-01-02
IL210580A0 (en)	2011-03-31
LUC00002I2 (me)	2017-04-04
NZ590638A (en)	2012-06-29
US7973040B2 (en)	2011-07-05
CO6351757A2 (es)	2011-12-20
JP2011528713A (ja)	2011-11-24
KR20110036627A (ko)	2011-04-07
AU2009274190A1 (en)	2010-01-28
RS52534B (en)	2013-04-30
PT2310095E (pt)	2012-11-16
HRP20120866T1 (hr)	2013-01-31
BRPI0916235A2 (pt)	2018-03-13
NO2017004I2 (no)	2017-01-20
DK2310095T3 (da)	2012-12-10
CA2731177C (en)	2013-10-29
ES2491090T3 (es)	2014-09-05
IL210580A (en)	2014-08-31
KR101313675B1 (ko)	2013-10-02
US8080654B2 (en)	2011-12-20
PL2540350T3 (pl)	2014-10-31
CA2731177A1 (en)	2010-01-28
UA100436C2 (en)	2012-12-25
NL300857I2 (me)	2017-04-25

Publication	Publication Date	Title
HUS1700001I1 (hu)	2017-02-28	Makrociklusos kinoxalin vegyületek, mint HCV NS3 proteáz inhibitorok
HUS1500020I1 (hu)	2018-12-28	Makrociklusos Hepatitis C szerin proteáz inhibitorok
BRPI0807887A2 (pt)	2014-06-17	Compostos macrocíclicos como inibidores de hcv ns3 protease.
HK1148739A1 (en)	2011-09-16	Hcv protease inhibitors hcv
IL195515A0 (en)	2011-08-01	Macrocyclic oximyl hepatitis c protease inhibitors
IL198401A0 (en)	2010-02-17	Hcv ns3 protease inhibitors
HK1144198A1 (en)	2011-02-02	Macrocyclic serine protease inhibitors
EP2224801A4 (en)	2011-09-28	MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE
BRPI0923184A2 (pt)	2019-09-24	inibidores de hcv ns3 protease
EP2245015A4 (en)	2012-05-30	DIFLUORATED TRIPEPTIDES AS INHIBITORS OF HCV SERINE PROTEASE
EP2432318A4 (en)	2012-11-21	NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
ZA200902475B (en)	2010-03-31	HCV NS3 Protease Inhibitors
ZA200810235B (en)	2009-10-28	Macrocyclic oximyl hepatitis C protease inhibitors